Continued treatment with TG Therapeutics’ Briumvi (ublituximab) provides sustained clinical benefits for people with relapsing forms of multiple sclerosis (MS), particularly if started earlier. That’s according to data from the ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) Phase 3 clinical trials and their ongoing open-label extension (NCT04130997). After five years of follow-up, more than 80% […]
The post MS patients see lasting benefits from Briumvi treatment, study says appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com